AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24667169 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity pulsed ultrasound (LIPUS)
Number of subjects: 23
Study 24667169 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 21857363 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning Training Group (MTG, training times 0700‐0800 hours, n = 10)
Number of subjects: 31
Study 21857363 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening Training Group (ETG, training times 1700‐1800 hours, n = 11)
Number of subjects: 31
Study 21857363 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG, n = 10)
Number of subjects: 31
Study 21857363 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapering after training (2 weeks)
Number of subjects: 31
Study 21857363 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of MTG and ETG after training and tapering
Number of subjects: 31
Study 20979100 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ciprofloxacin
Number of subjects: 100
Study 20979100 — intervention group
Group type: COMPARATOR
Intervention: Oral amoxicillin
Number of subjects: 100
Study 20979100 — intervention group
Group type: COMPARATOR
Intervention: Topical saline
Number of subjects: 100
Study 18568960 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemical Protective Clothing (CPN) at 21 degrees C
Number of subjects: 11
Study 18568960 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemical Protective Clothing (CPC) at -5 degrees C
Number of subjects: 11
Study 18568960 — intervention group
Group type: COMPARATOR
Intervention: Field Combat Uniform (U) at 21 degrees C
Number of subjects: 11
Study 16423096 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity (HI) intervention: 4 face-to-face visits with a trained pharmacist, patient-specific education about hypertension, home BP monitoring device provided.
Number of subjects: 125
Study 16423096 — intervention group
Group type: COMPARATOR
Intervention: Low-Intensity (LI) intervention: Pharmacists measured BP in the pharmacy and referred patients to their physician.
Number of subjects: 125
Study 11821634 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ)
Number of subjects: 22
Study 11821634 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril (ACE inhibitor)
Number of subjects: 22
Study 11821634 — intervention group
Group type: EXPERIMENTAL
Intervention: HCTZ or Quinapril
Number of subjects: 22
Study 11821634 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin + Betaxolol (combined alpha + beta blockade)
Number of subjects: 22
Study 8957730 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum hepatitis C virus (HCV) titers in patients with hepatocellular carcinoma (HCC)
Number of subjects: 94
Study 8957730 — intervention group
Group type: COMPARATOR
Intervention: Serum hepatitis C virus (HCV) titers in patients with chronic persistent hepatitis (CPH)
Number of subjects: 94
Study 8957730 — intervention group
Group type: COMPARATOR
Intervention: Serum hepatitis C virus (HCV) titers in patients with chronic active hepatitis and/or liver cirrhosis (CAH/LC)
Number of subjects: 94
Study 8957730 — intervention group
Group type: EXPERIMENTAL
Intervention: HCV type 1b infection
Number of subjects: 94
Study 2390429 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 14
Study 2390429 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 micrograms atropine (A300)
Number of subjects: 14
Study 2390429 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 micrograms atropine (A600)
Number of subjects: 14
Study 2390429 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine (both doses)
Number of subjects: 14
Study 7308274 — intervention group
Group type: EXPERIMENTAL
Intervention: F‐CBZ, DAK (200 mg single dose)
Number of subjects: 21
Study 7308274 — intervention group
Group type: COMPARATOR
Intervention: Tegretol (200 mg single dose)
Number of subjects: 21
Study 7308274 — intervention group
Group type: EXPERIMENTAL
Intervention: F‐CBZ, DAK
Number of subjects: 21
Study 7308274 — intervention group
Group type: COMPARATOR
Intervention: Tegretol
Number of subjects: 21
Study 7308274 — intervention group
Group type: EXPERIMENTAL
Intervention: F‐CBZ, DAK and Tegretol
Number of subjects: 21
Study 30737999 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal microbiome
Number of subjects: 198
Study 30737999 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin microbiome
Number of subjects: 198
Study 30737999 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of Staphylococcus aureus on skin lesions
Number of subjects: 198
Study 30737999 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal and skin microbial communities
Number of subjects: 198
Study 29241199 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin therapy
Number of subjects: 4038
Study 25401463 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (HBO) therapy (40 sessions at 1.5 ATA)
Number of subjects: 72
Study 25401463 — intervention group
Group type: EXPERIMENTAL
Intervention: Sham procedure (40 sessions of room air at 1.2 ATA)
Number of subjects: 72
Study 25401463 — intervention group
Group type: COMPARATOR
Intervention: No supplemental chamber procedures (control group)
Number of subjects: 72
Study 23752553 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive expiratory pressure (PEP) therapy (10‐20 cm H2O)
Number of subjects: 12
Study 23752553 — intervention group
Group type: COMPARATOR
Intervention: Controlled huffing and coughing
Number of subjects: 12
Study 22656678 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol nanoemulsion (NE Group)
Number of subjects: 150
Study 22656678 — intervention group
Group type: COMPARATOR
Intervention: Propofol emulsion (CONT Group)
Number of subjects: 150
Study 19374971 — intervention group
Group type: EXPERIMENTAL
Intervention: Narratives containing indication-unrelated medical or psychiatric adverse events
Number of subjects: 45
Study 19374971 — intervention group
Group type: COMPARATOR
Intervention: Narratives without indication-unrelated medical or psychiatric adverse events
Number of subjects: 45
Study 19374971 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychiatric adverse event unrelated to the disease
Number of subjects: 45
Study 19374971 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical adverse event unrelated to the disease
Number of subjects: 45
Study 17318022 — intervention group
Group type: EXPERIMENTAL
Intervention: LCT genotype CC (associated with lactose malabsorption)
Number of subjects: 239
Study 17318022 — intervention group
Group type: EXPERIMENTAL
Intervention: LCT genotype TC
Number of subjects: 239
Study 17318022 — intervention group
Group type: EXPERIMENTAL
Intervention: LCT genotype TT (lactase persistence)
Number of subjects: 239
Study 17318022 — intervention group
Group type: EXPERIMENTAL
Intervention: Low milk intake
Number of subjects: 239
Study 17318022 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium consumption rates
Number of subjects: 239
Study 15203784 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine nasal spray (fast delivery)
Number of subjects: 30
Study 15203784 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine patch (slow delivery)
Number of subjects: 30
Study 15203784 — intervention group
Group type: COMPARATOR
Intervention: Placebo condition (placebo spray and patch)
Number of subjects: 30
Study 15203784 — intervention group
Group type: COMPARATOR
Intervention: Nicotine patch condition (with placebo spray)
Number of subjects: 30
Study 15203784 — intervention group
Group type: COMPARATOR
Intervention: Nicotine spray condition (with placebo patch)
Number of subjects: 30
Study 11181775 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV16 L1 VLP vaccine without adjuvant (10-50 microg doses)
Number of subjects: 0
Study 11181775 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV16 L1 VLP vaccine with MF59 adjuvant (10-50 microg doses)
Number of subjects: 0
Study 11181775 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV16 L1 VLP vaccine with alum adjuvant (10-50 microg doses)
Number of subjects: 0
Study 11181775 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10333899 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin lispro
Number of subjects: 14
Study 10333899 — intervention group
Group type: COMPARATOR
Intervention: Regular insulin
Number of subjects: 14
Study 8555958 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine nasal spray (NNS)
Number of subjects: 255
Study 8555958 — intervention group
Group type: COMPARATOR
Intervention: Piperine placebo
Number of subjects: 255
Study 2114722 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant portal infusion of 5‐fluorouracil in combination with mitomycin C
Number of subjects: 469
Study 2114722 — intervention group
Group type: COMPARATOR
Intervention: Radical surgery alone
Number of subjects: 469
Study 2114722 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (strict adherence)
Number of subjects: 469
Study 2114722 — intervention group
Group type: COMPARATOR
Intervention: No or incomplete chemotherapy
Number of subjects: 469
Study 356601 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritodrine (N = 14)
Number of subjects: 29
Study 356601 — intervention group
Group type: COMPARATOR
Intervention: Placebo (N = 15)
Number of subjects: 29
Study 31202086 — intervention group
Group type: EXPERIMENTAL
Intervention: Certain condition (high-calorie meal with nutritional information)
Number of subjects: 85
Study 31202086 — intervention group
Group type: COMPARATOR
Intervention: Uncertain condition (meal alone)
Number of subjects: 85
Study 31202086 — intervention group
Group type: EXPERIMENTAL
Intervention: Both conditions (certain and uncertain)
Number of subjects: 85
Study 28381814 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated care intervention and participatory workplace intervention
Number of subjects: 150
Study 28381814 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (CAU)
Number of subjects: 150
Study 26037513 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 g intrinsically L-[1-(13)C]phenylalanine-labeled protein ingestion
Number of subjects: 23
Study 24050416 — intervention group
Group type: EXPERIMENTAL
Intervention: COPE (Creating Opportunities for Personal Empowerment) Healthy Lifestyles TEEN Program
Number of subjects: 779
Study 21945768 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemomechanical method with Carisolv(TM) system
Number of subjects: 192
Study 21945768 — intervention group
Group type: COMPARATOR
Intervention: Traditional mechanical method
Number of subjects: 192
Study 19912735 — intervention group
Group type: EXPERIMENTAL
Intervention: Wuling Capsule (WC)
Number of subjects: 96
Study 19912735 — intervention group
Group type: COMPARATOR
Intervention: Gengnianan Tablet (control)
Number of subjects: 96
Study 17215115 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 64 microg
Number of subjects: 0
Study 17215115 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol 9 microg
Number of subjects: 0
Study 17215115 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 64 microg + Formoterol 9 microg
Number of subjects: 0
Study 17215115 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 14674971 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 2.5 mg kg(‐1) followed by remifentanil 1 microg kg(‐1) (group PR)
Number of subjects: 30
Study 14674971 — intervention group
Group type: COMPARATOR
Intervention: Remifentanil 1 microg kg(‐1) followed by propofol 2.5 mg kg(‐1) (group RP)
Number of subjects: 30
Study 11739068 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation treatment with nortriptyline-plus-perphenazine
Number of subjects: 29
Study 11739068 — intervention group
Group type: COMPARATOR
Intervention: Continuation treatment with nortriptyline-plus-placebo
Number of subjects: 29
Study 9770818 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol without narcotic analgesics
Number of subjects: 30
Study 9770818 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol combined with pyritramide (0.4 mg/kg)
Number of subjects: 30
Study 9770818 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus injection of propofol
Number of subjects: 30
Study 9770818 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus injection of thiopental
Number of subjects: 30
Study 9357148 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose choline (500 mg TDS)
Number of subjects: 0
Study 9357148 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose choline (1000 mg TDS)
Number of subjects: 0
Study 9357148 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sorbitol)
Number of subjects: 0
Study 2682004 — intervention group
Group type: EXPERIMENTAL
Intervention: Meciadanol
Number of subjects: 0
Study 2682004 — intervention group
Group type: EXPERIMENTAL
Intervention: Maalox
Number of subjects: 0
Study 2682004 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate
Number of subjects: 0
Study 2682004 — intervention group
Group type: COMPARATOR
Intervention: Nasogastric aspiration
Number of subjects: 0
Study 170634 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium fluoride high Beta‐phase calcium pyrophosphate dentifrice (1000 ppm fluoride)
Number of subjects: 567
Study 170634 — intervention group
Group type: COMPARATOR
Intervention: Calcium pyrophosphate dentifrice without sodium fluoride (control)
Number of subjects: 567
Study 31177717 — intervention group
Group type: EXPERIMENTAL
Intervention: Index method
Number of subjects: 2
Study 31177717 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive method
Number of subjects: 2
Study 31177717 — intervention group
Group type: COMPARATOR
Intervention: Ratio method
Number of subjects: 2
Study 29310326 — intervention group
Group type: EXPERIMENTAL
Intervention: remifentanil (infused at 2 μg/kg/h)
Number of subjects: 50
Study 29310326 — intervention group
Group type: COMPARATOR
Intervention: dexmedetomidine (infused at 0.4 μg/kg/h)
Number of subjects: 50
Study 26663645 — intervention group
Group type: EXPERIMENTAL
Intervention: U-type TVT-Secur approach
Number of subjects: 115
Study 26663645 — intervention group
Group type: EXPERIMENTAL
Intervention: H-type TVT-Secur approach
Number of subjects: 115
Study 26663645 — intervention group
Group type: EXPERIMENTAL
Intervention: Both U-type and H-type TVT-Secur approaches
Number of subjects: 115
Study 22135229 — intervention group
Group type: EXPERIMENTAL
Intervention: Early palliative care interventions directed at patient symptoms and caregiver support
Number of subjects: 191
Study 22135229 — intervention group
Group type: EXPERIMENTAL
Intervention: Not providing care for other dependents
Number of subjects: 191
Study 22135229 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver's work situation
Number of subjects: 191
Study 22107011 — intervention group
Group type: EXPERIMENTAL
Intervention: Referral to gynaecologist
Number of subjects: 1402
Study 22107011 — intervention group
Group type: EXPERIMENTAL
Intervention: Referral to gynaecological oncologist
Number of subjects: 1402
Study 22107011 — intervention group
Group type: EXPERIMENTAL
Intervention: Referral rates for ovarian cancer
Number of subjects: 1402
Study 22107011 — intervention group
Group type: EXPERIMENTAL
Intervention: Referral rates for cervical cancer
Number of subjects: 1402
Study 22107011 — intervention group
Group type: EXPERIMENTAL
Intervention: Referral rates for endometrial cancer
Number of subjects: 1402
Study 22107011 — intervention group
Group type: COMPARATOR
Intervention: Metropolitan vs Rural GPs
Number of subjects: 1402
Study 22107011 — intervention group
Group type: COMPARATOR
Intervention: Patient factors
Number of subjects: 1402
Study 19632953 — intervention group
Group type: EXPERIMENTAL
Intervention: Valganciclovir (VGCV)
Number of subjects: 338
Study 19632953 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 338
Study 16180017 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation of an evidence-based skin protection programme with a top-down and bottom-up strategy including management system and educational programme.
Number of subjects: 0
Study 16180017 — intervention group
Group type: EXPERIMENTAL
Intervention: Activities of change agents as part of the intervention.
Number of subjects: 0
Study 16180017 — intervention group
Group type: COMPARATOR
Intervention: Establishment of a formal management system alone.
Number of subjects: 0
Study 15274171 — intervention group
Group type: EXPERIMENTAL
Intervention: EX/RP
Number of subjects: 46
Study 15274171 — intervention group
Group type: EXPERIMENTAL
Intervention: EX/RP+CMI
Number of subjects: 46
Study 15274171 — intervention group
Group type: COMPARATOR
Intervention: CMI
Number of subjects: 46
Study 15274171 — intervention group
Group type: COMPARATOR
Intervention: PBO
Number of subjects: 46
Study 11413351 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol (24 microg twice daily by Turbuhaler)
Number of subjects: 19
Study 11413351 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol (100 microg twice daily by Diskhaler)
Number of subjects: 19
Study 11413351 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 9430359 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 million units (MU) rIFN‐alpha2b
Number of subjects: 100
Study 9430359 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 million units (MU) rIFN‐alpha2b
Number of subjects: 100
Study 9430359 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 8427642 — intervention group
Group type: EXPERIMENTAL
Intervention: Thera‐Pulse (Kinetic Concepts)
Number of subjects: 79
Study 8427642 — intervention group
Group type: COMPARATOR
Intervention: Geo‐Matt (SpanAmerica)
Number of subjects: 79
Study 8427642 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage II ulcer patients
Number of subjects: 79
Study 3025051 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary fiber
Number of subjects: 120
Study 3025051 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 28455162 — intervention group
Group type: EXPERIMENTAL
Intervention: Sphincterotomy
Number of subjects: 103
Study 28455162 — intervention group
Group type: COMPARATOR
Intervention: Sham intervention
Number of subjects: 103
Study 28455162 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (sphincterotomy)
Number of subjects: 103
Study 28455162 — intervention group
Group type: COMPARATOR
Intervention: No active treatment
Number of subjects: 103
Study 28078544 — intervention group
Group type: EXPERIMENTAL
Intervention: Parker Flex-Tip™ nasal endotracheal tube (ETT) with a posterior facing bevel
Number of subjects: 60
Study 28078544 — intervention group
Group type: COMPARATOR
Intervention: Standard nasal RAE endotracheal tube with a leftward facing bevel
Number of subjects: 60
Study 26178282 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraarticular etanercept injection
Number of subjects: 0
Study 26178282 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual analog scale of pain
Number of subjects: 0
Study 26178282 — intervention group
Group type: EXPERIMENTAL
Intervention: Functionality assessment
Number of subjects: 0
Study 22952137 — intervention group
Group type: EXPERIMENTAL
Intervention: 6.4% maltodextrin solution (CHO)
Number of subjects: 10
Study 22952137 — intervention group
Group type: COMPARATOR
Intervention: No solution (CON)
Number of subjects: 10
Study 22952137 — intervention group
Group type: COMPARATOR
Intervention: Water (WA)
Number of subjects: 10
Study 21733322 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-rich extract (500 mg daily)
Number of subjects: 34
Study 21733322 — intervention group
Group type: COMPARATOR
Intervention: PF-rich extract (n 12)
Number of subjects: 34
Study 19502035 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-warmed colloid followed by pre-warmed crystalloid solution
Number of subjects: 30
Study 19502035 — intervention group
Group type: COMPARATOR
Intervention: Non-warmed infusion
Number of subjects: 30
Study 16430793 — intervention group
Group type: EXPERIMENTAL
Intervention: Single injection (droperidol 2.5 mg)
Number of subjects: 120
Study 16430793 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous group (droperidol 2.5 mg 2 day(‐1))
Number of subjects: 120
Study 16430793 — intervention group
Group type: COMPARATOR
Intervention: Control (no droperidol)
Number of subjects: 120
Study 12631529 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS) in the basal ganglia (internal globus pallidum)
Number of subjects: 0
Study 10883558 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment (CBT) with breathing retraining (BR)
Number of subjects: 77
Study 10883558 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment (CBT) without breathing retraining (BR)
Number of subjects: 77
Study 10883558 — intervention group
Group type: COMPARATOR
Intervention: Delayed-treatment control
Number of subjects: 77
Study 9166393 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclical etidronate (400 mg/day for 2 weeks, followed by 11 weeks of 500 mg/day elemental oral calcium)
Number of subjects: 24
Study 9166393 — intervention group
Group type: COMPARATOR
Intervention: GnRH agonist alone (triptorelin 3.75 mg intramuscularly every 4 weeks)
Number of subjects: 24
Study 9166393 — intervention group
Group type: COMPARATOR
Intervention: Elemental calcium (500 mg/day continuously)
Number of subjects: 24
Study 8222488 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednicarbate 0.25%
Number of subjects: 60
Study 8222488 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone aceponate
Number of subjects: 60
Study 8222488 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone buteprate 0.1%
Number of subjects: 60
Study 8222488 — intervention group
Group type: COMPARATOR
Intervention: Betamethasone 17-valerate 0.1%
Number of subjects: 60
Study 8222488 — intervention group
Group type: COMPARATOR
Intervention: Hydrocortisone 1%
Number of subjects: 60
Study 8222488 — intervention group
Group type: COMPARATOR
Intervention: Drug-free vehicles
Number of subjects: 60
Study 2988108 — intervention group
Group type: EXPERIMENTAL
Intervention: Guar gum (Guarem), 5 g
Number of subjects: 0
Study 2988108 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiber-enriched wheat bran (Fiberform), 10.5 g
Number of subjects: 0
Study 2988108 — intervention group
Group type: COMPARATOR
Intervention: Control (no fiber preparation)
Number of subjects: 0
Study 29870556 — intervention group
Group type: EXPERIMENTAL
Intervention: Olesoxime (Group O)
Number of subjects: 74
Study 29870556 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Group P)
Number of subjects: 74
Study 29870556 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Groups O and P
Number of subjects: 74
Study 27155880 — intervention group
Group type: EXPERIMENTAL
Intervention: Work It Out Together DVD
Number of subjects: 170